An interventional study of Artemisia and green tea extracts and Placebo in Functional Dysphonia, sponsored by Pusan National University Yangsan Hospital. Completed at 1 site in South Korea. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Pusan National University Yangsan Hospital · Not applicable, Interventional, and Supportive care
This clinical trial aims to determine whether Artemisia and green tea extracts promote gastric mucosal health in adults with functional dyspepsia and to assess its safety.
The main questions are:
Researchers will compare Artemisia and green tea extracts to placebo to evaluate their effectiveness in promoting gastric mucosal health.
Participants will:
Pusan National University Yangsan Hospital is the lead sponsor of 106 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This group takes Artemisia and green tea extracts for 8 weeks.
Dietary Supplement: Artemisia and green tea extracts
This group takes a placebo for 8 weeks.
Dietary Supplement: Placebo
Artemisia and green tea extracts 700 mg/day for 8 weeks
Placebo 700 mg/day for 8 weeks
The Korean version of the Gastrointestinal Symptom Rating Scale: Total score
Measured at baseline and 8 weeks. This is a 4-point Likert scale for each of the 15 items, with scores ranging from 0 to 3. A score of 0 indicates no symptoms, and 3 represents very severe symptoms. The higher the overall score, the more severe the gastrointestinal symptoms. The minimum value was 0, and the maximum value was 45, and higher scores mean a worse outcome.
Time frame: From enrollment to the end of treatment at 8 weeks
The Korean version of the Gastrointestinal Symptom Rating Scale: Subtotal scores of upper abdomen
Measured at baseline and 8 weeks. This is a 4-point Likert scale for each of the 8 items, with scores ranging from 0 to 3. A score of 0 indicates no symptoms, and 3 represents very severe symptoms. The higher the overall score, the more severe the gastrointestinal symptoms. The minimum value was 0, and the maximum value was 21, and higher scores mean a worse outcome.
Time frame: From enrollment to the end of treatment at 8 weeks
Visual Analogue Scale for evaluating gastric mucosal improvement
Measured at baseline and 8 weeks. The minimum value was 0 and the maximum value was 100, and higher scores mean a worse outcome.
Time frame: From enrollment to the end of treatment at 8 weeks
Gastrointestinal symptom score
Measured at baseline and 8 weeks. The minimum value was 0 and the maximum value was 40, and higher scores mean a worse outcome. For each gastrointestinal symptom, the minimum value was 0, and the maximum value was 4, and higher scores mean a worse outcome.
Time frame: From enrollment to the end of treatment at 8 weeks
Patient's global assessment score
Measured at baseline and 8 weeks. The 5-point Likert scale for the Patient's Global Assessment Score is a self-reported tool where patients rate their disease activity. It uses an order scale, with 5 indicating "Very Good" and 1 indicating "Poor." The patient evaluates their condition based on this scale: Very Good-Good-Fair-Unchanged-Poor.
Time frame: From enrollment to the end of treatment at 8 weeks
Pepsinogen I level (ng/mL)
Measured at baseline and 8 weeks
Time frame: From enrollment to the end of treatment at 8 weeks
Pepsinogen II level (ng/mL)
Measured at baseline and 8 weeks
Time frame: From enrollment to the end of treatment at 8 weeks
Pepsinogen I/Pepsinogen II ratio
Measured at baseline and 8 weeks
Time frame: From enrollment to the end of treatment at 8 weeks
Gastrin-17 level (ng/L)
Measured at baseline and 8 weeks
Time frame: From enrollment to the end of treatment at 8 weeks
Helicobacter pylori IgG titer (units)
Measured at baseline and 8 weeks
Time frame: From enrollment to the end of treatment at 8 weeks
High-sensitive C-reactive protein (mg/dL)
Measured at baseline and 8 weeks
Time frame: From enrollment to the end of treatment at 8 weeks
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pusan National University Yangsan Hospital